Treatment of breast cancer in young women: do we need more aggressive therapies?

Por Cancello, Giuseppe, Montagna, Emilia
Publicado em 2013

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer

Por Cancello, Giuseppe, Montagna, Emilia, D'Agostino, Diego, Giuliano, Mario, Giordano, Antonio, Di Lorenzo, Giuseppe, Plaitano, Monica, De Placido, Sabino, De Laurentiis, Michele
Publicado em 2008

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-0...

Por Pruneri, Giancarlo, Gray, Kathryn P., Vingiani, Andrea, Viale, Giuseppe, Curigliano, Giuseppe, Criscitiello, Carmen, Láng, István, Ruhstaller, Thomas, Gianni, Lorenzo, Goldhirsch, Aron, Kammler, Roswitha, Price, Karen N., Cancello, Giuseppe, Munzone, Elisabetta, Gelber, Richard D., Regan, Meredith M., Colleoni, Marco
Publicado no Breast Cancer Res Treat (2016)